VV-RT · Research pen
Retatrutide 40mg research pen
The Vivora Retatrutide 40mg research pen is one pre-filled pen labelled 40mg, packed in its own sealed, batch-coded window box.
Triple receptor agonist: GLP‑1, GIP and glucagon
- Label strength: 40mg
- Pens per box: 1
- In the box: 1 pre-filled research pen, a sealed window box and a printed batch code
- Price: £160 per box, with the UK delivery charge shown before payment
- Availability: checked live when this page loads, and again at checkout
- Batch report: published, see the lab-reports page
For laboratory research only. Not for human or animal consumption.
Compare the full range · Research pens and vials: what to compare · How to read a peptide lab report
Check packaging and published batch records · Research use policy · UK delivery
Key facts
Also known as Reta, GLP-3, LY3437943
| Compound | Retatrutide (LY3437943) |
|---|---|
| Label strength | 40mg |
| Format | Pre-filled research pen, sealed window box |
| Pens per box | 1 |
| Price | £160 per box |
| Price per mg | £4.00 per mg (£160 ÷ 40mg) |
| UK delivery | £4.95 per order |
More about Retatrutide
About retatrutide
Retatrutide, research code LY3437943, is a synthetic peptide with agonist activity at three receptors: the glucagon, GIP and GLP-1 receptors. Scientists at Eli Lilly and Company first described it in 2022, reporting that in vitro its glucagon and GLP-1 receptor activity is balanced while its GIP receptor activity is greater. Tirzepatide targets two of those three receptors.
The FDA substance registry records the molecule as a 39-amino-acid chain with an amidated C-terminus. Three positions hold non-coded amino acids, 2-methylalanine at positions 2 and 20 and 2-methyl-leucine at position 13, and the lysine at position 17 carries a C20 fatty diacid attached through a linker.
- Research code
- LY3437943
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731 g/mol
- Chain length
- 39 amino acids
- Receptor targets
- Glucagon, GIP and GLP-1 receptors
- Class
- Triple receptor agonist peptide
- Development status
- Investigational; highest phase 3
Sources
- Coskun T et al. Cell Metab. 2022: research code, receptor targets and in vitro receptor activity
- PubChem CID 171934787: molecular formula and molecular weight
- FDA Global Substance Registration System: CAS number, chain length and modified residues
- ChEMBL CHEMBL5095485: highest phase 3, no approval recorded
Retatrutide vs tirzepatide
The two are easy to confuse. Both are synthetic 39-amino-acid peptides from Eli Lilly and Company, both carry a C20 fatty diacid on a lysine side chain, and they share their last 11 residues, GGPSSGAPPPS. The defining difference is the receptor list: retatrutide adds the glucagon receptor to the GIP and GLP-1 receptors that tirzepatide targets.
| Compared | Retatrutide | Tirzepatide |
|---|---|---|
| Research code | LY3437943 | LY3298176 |
| Glucagon receptor | Agonist | Not a target |
| GIP receptor | Agonist | Agonist |
| GLP-1 receptor | Agonist | Agonist |
| Chain length | 39 amino acids | 39 amino acids |
| Non-coded residues | 3, at positions 2, 13 and 20 | 2, at positions 2 and 13 |
| C20 fatty diacid on | Lysine 17 | Lysine 20 |
| Molecular formula | C221 | C225 |
| Highest stage | Phase 3, investigational | Approved, first in 2022 |
| Vivora pen | 40mg, £160 per box | 40mg, £100 per box |
Vivora sells both as 40mg research pens; see Tirzepatide 40mg.
Sources
- FDA GSRS, tirzepatide: tirzepatide sequence and modified residues
- Coskun T et al. Mol Metab. 2018: tirzepatide's two receptor targets and fatty diacid position
- ChEMBL CHEMBL4297839: tirzepatide's approved stage and first approval in 2022
Clinical research programme
Retatrutide's development is registered on ClinicalTrials.gov. Eli Lilly and Company is the lead sponsor of every phase 2 and phase 3 record listed here: 14 phase 3 records, nine of them run under the name TRIUMPH. This section lists registry facts only, the study number, phase, sponsor and status, and does not summarise any study's findings.
| Phase 3 study | Record | Status |
|---|---|---|
| TRIUMPH-1 | NCT05929066 | Completed |
| TRIUMPH-2 | NCT05929079 | Completed |
| TRIUMPH-3 | NCT05882045 | Completed |
| TRIUMPH-4 | NCT05931367 | Completed |
| TRIUMPH-5 | NCT06662383 | Active, not recruiting |
| TRIUMPH-6 | NCT06859268 | Active, not recruiting |
| TRIUMPH-7 | NCT07035093 | Active, not recruiting |
| TRIUMPH-8 | NCT07232719 | Active, not recruiting |
| TRIUMPH-9 | NCT07357415 | Active, not recruiting |
Five further phase 3 records: NCT06354660 (completed), NCT06260722, NCT06297603 and NCT06383390 (active, not recruiting) and NCT07165028 (recruiting). Phase 2 records: NCT04881760, the study published in 2023, plus NCT04867785 and NCT05936151, all three completed. A series of phase 1 studies is registered as well.
Sources
- ClinicalTrials.gov, retatrutide records: study records, phases, lead sponsor and statuses
- Jastreboff AM et al. N Engl J Med. 2023: publication of the phase 2 study NCT04881760
What 40mg on the label means
The 40mg printed on the label is the stated amount of retatrutide in the single pre-filled pen in the box. With one pen per box, 40mg is both the pen figure and the box total, so there is nothing to multiply.
At £160 per box that works out at £4.00 per mg (£160 ÷ 40mg). Listings elsewhere may quote mg per vial, per pen or per pack of several containers; convert each one to a total per box before comparing prices per mg.
Names you will see
Retatrutide turns up under several names. Only retatrutide and LY3437943 appear in the scientific and regulatory record; the CAS number identifies the substance itself.
| Name | What it is |
|---|---|
| Retatrutide | Non-proprietary name (INN and USAN) |
| LY3437943 | Eli Lilly and Company research code, also written LY-3437943 |
| Reta | Informal short form used in listings and searches |
| GLP-3 | Informal listing name; not listed by ChEMBL or the FDA substance registry |
| 2381089-83-2 | CAS registry number |
Sources
- ChEMBL CHEMBL5095485: INN and USAN names and research codes
- FDA GSRS, retatrutide: recorded names and CAS number
Buying from Vivora
UK delivery is £4.95 per order, shown before payment. Every pen is filled fresh for your order, and orders paid by 3pm, Monday to Thursday, are dispatched the same day. Pay by UK bank transfer after you place your order. Unopened boxes can be returned within 30 days of delivery for a full refund. Store sealed at 2 to 8°C. See delivery information, returns and refunds and our guide to research pens and vials.
Questions, answered.
How much is a 40mg reta pen?
Vivora's Retatrutide 40mg research pen is £160 per box, with one pre-filled pen in each box. That is £4.00 per mg of label strength. UK delivery is £4.95 per order, shown before payment.
What strengths do retatrutide pens come in?
Vivora sells one format: a pre-filled research pen labelled 40mg, one pen per box. There is no other retatrutide strength in the range. Other suppliers state amounts per pen, per vial or per pack, so compare the total mg in a box rather than the headline figure.
What is GLP-3?
An informal name that some listings and searches use for retatrutide. It is not a scientific name: ChEMBL and the FDA substance registry list the compound as retatrutide or LY3437943, and neither lists GLP-3 among its names.
Is retatrutide the same as tirzepatide?
No. They are different molecules with different research codes, LY3437943 and LY3298176, and different amino acid sequences. Retatrutide acts at the glucagon, GIP and GLP-1 receptors; tirzepatide at the GIP and GLP-1 receptors only. Vivora sells them as two separate 40mg pens; see Tirzepatide.
Who developed retatrutide?
Eli Lilly and Company. Lilly scientists published its discovery in Cell Metabolism in 2022 under the code LY3437943, and Lilly is the lead sponsor of all 14 phase 3 records for it on ClinicalTrials.gov, including the TRIUMPH studies.
Is retatrutide licensed in the UK?
No. Retatrutide is investigational and is not a licensed medicine in the UK. ChEMBL records its highest stage as phase 3 with no approval, and several of its phase 3 studies are still active on ClinicalTrials.gov. Vivora's pen is sold for laboratory research only.
What does LY3437943 mean?
It is Eli Lilly and Company's research code for retatrutide, sometimes written LY-3437943. The code is used in the 2022 discovery paper and in the titles of the compound's ClinicalTrials.gov records; retatrutide is its non-proprietary (INN) name.